InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Greenwich LifeSciences, Inc.

GLSI Clue Score23
United States Fiscal year ends December CIK 0001799788
$16.53 +9.18% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $16.53 −55.85% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 25 Sep 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Operating income−3.4Net income−3.4Fiscal year 2020Operating income−1.9Net income−1.9Fiscal year 2021Operating income−4.6Net income−4.6Fiscal year 2022Operating income−8.0Net income−7.8EPS, diluted−0.61Fiscal year 2023Operating income−9.3Net income−8.9EPS, diluted−0.69Fiscal year 2024Operating income−17.6Net income−17.4EPS, diluted−1.34Fiscal year 2025Operating income−19.4Net income−19.4EPS, diluted−1.43
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −3.4 −1.9 −4.6 −8.0 −9.3 −17.6 −19.4
Net income −3.4 −1.9 −4.6 −7.8 −8.9 −17.4 −19.4
Growth
EPS, diluted n/a n/a n/a −0.61 −0.69 −1.34 −1.43
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2019Operating cash flow−0.3Fiscal year 2020Operating cash flow−1.2Fiscal year 2021Operating cash flow−4.3Fiscal year 2022Operating cash flow−6.2Buybacks−7.5Fiscal year 2023Operating cash flow−6.5Fiscal year 2024Operating cash flow−7.3Fiscal year 2025Operating cash flow−9.9
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.3 −1.2 −4.3 −6.2 −6.5 −7.3 −9.9
Buybacks n/a n/a n/a −7.5 n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash0.0Shareholders’ equity−1.4Fiscal year 2020Cash28.7Shareholders’ equity27.6Fiscal year 2021Cash27.2Shareholders’ equity26.8Fiscal year 2022Cash13.5Shareholders’ equity13.2Fiscal year 2023Cash7.0Shareholders’ equity6.7Fiscal year 2024Cash4.1Shareholders’ equity0.9Fiscal year 2025Cash6.2Shareholders’ equity0.4
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.0 28.7 27.2 13.5 7.0 4.1 6.2
Shareholders’ equity −1.4 27.6 26.8 13.2 6.7 0.9 0.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
2.6 1.1 3.6 6.5 7.7 15.5 17.2
0.8 0.8 1.0 1.6 1.6 2.2 2.2
−3.4 −1.9 −4.6 −8.0 −9.3 −17.6 −19.4
Growth
−3.4 −1.9 −4.6 −7.8 −8.9 −17.4 −19.4
Growth
Per share
n/a n/a −0.35 −0.61 −0.69 −1.34 −1.43
n/a n/a n/a −0.61 −0.69 −1.34 −1.43
Growth
n/a n/a n/a n/a 12.8 13.0 13.5
n/a n/a n/a 12.9 12.8 13.0 13.5
Growth −0.5% +1.3% +4.0%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.